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ABSTRACT
Objective: To study the effectiveness and morbidity of adding hygroscopic cervical dilators to pros-
taglandin gel for cervical ripening and labor induction.
Study design: Patients of at least 34 weeks’ gestation with a medical indication for induction of
labor and with a modified Bishop score of 5 or less were randomized to receive either prostaglandin
gel or prostaglandin gel with hygroscopic cervical dilators. Primary outcomes were time to delivery,
change in cervical score, and infection. Secondary outcomes included cesarean delivery rate and
deliveries before 24 hours of induction. Continuous variables were analyzed by Wilcoxon sum rank
test and categorical data by chi-square or Fisher exact test, with P < 0.05 being significant.
Results: Seventeen patients were randomized to intracervical prostaglandin alone and 23 patients
received intracervical prostaglandin plus hygroscopic dilators. No demographic differences were
noted between the groups. After six hours of ripening, the combined group achieved a greater
change in Bishop score (3.6 vs. 2.1, P 0.007) and tended to have a shorter induction time (21.7 vs.
26.4 hours, P 0.085). The combined therapy group had a higher infection rate than the prosta-
glandin-only group (59% vs. 12%, P 0.003).
Conclusion: Combining cervical dilators with prostaglandin gel provides more effective cervical
ripening and a more rapid induction to delivery interval than prostaglandin alone but with a sig-
nificant and prohibitive rate of infection. Infect. Dis. Obstet. Gynecol. 6:18-24, 1998.
(C) 1998 Wiley-Liss, Inc.
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abor induction is common in modern obstetrics,
with attention rightly directed toward the de-
velopment of effective cervical ripening and induc-
tion techniques. Prostaglandin gel, intracervical
mechanical devices, oral mifepristone, vaginal mi-
soprostol, and extraamniotic saline infusions are
some of the agents investigated in recent years. 1-6
The safety and efficacy of single-agent therapy
with prostaglandin Ez (PGEz) gel for preinduction
ripening of the cervix has been well docu-
mented.4-9 PGEz stimulates a change in the mo-
lecular structure of the cervix and can also cause
uterine contractions.9 There has been no docu-
mented increased risk of intrauterine infection
with the use of this agent either intracervically or
intravaginally. Hygroscopic cervical dilators have
also been investigated as a single-agent method of
preinduction cervical ripening.6,1- These dila-
tors absorb moisture through hygroscopic action,
drawing fluid from the cervical stroma, resulting in
softening of the tissue. As the dilators absorb fluid,
axial expansion causes mechanical dilation of the
cervix, as well as local production of endogenous
prostaglandin that may contribute to their mecha-
nism of action.-1 Findings on whether mechani-
cal dilators promote an increase in intrauterine in-
fection have not been consistent.6,-1z
In an attempt to shorten the time from indue-
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TABLE I. Modified Bishop scoring
Score
0 2
Dilation <0.5 cm 0.5-1.5 cm >1.5 cm
Effacement 0 -<50% >50%
Station -3 -2/-I 0
Cervical consistency Firm Medium Soft
Cervical position Posterior Mild Anterior
Jagani N, Schulman H, Fleischer A: Role of the cervix in induction of
labor. Obstet Gynecol 59: 21-25, 1982.
tion to delivery, a number of clinicians at our insti-
tution began combining the use of Dilapan (R) hy-
groscopic dilators (Gynotech, Middlesex, NJ) with
Prepidil Gel(R), the commercially available intracer-
vical PGEz preparation (Upjohn, Kalamazoo, MI).
Because of our concern regarding the efficacy and
safety of this approach, we undertook this random-
ized, controlled trial to compare prostaglandin gel
used in combination with hygroscopic dilators to
prostaglandin gel alone for cervical ripening.
MATERIALS AND METHODS
This study was performed at the University of Chi-
cago, Chicago Lying-in Hospital, between August
1, 1994, and May 1,1995, and all patients admitted
for induction of labor were invited to participate.
Inclusion criteria were gestational age of at least 34
weeks, a medical or obstetric indication for induc-
tion of labor, a modified Bishop score of 5 or less
(Table 1),13 cervical dilation less than 1 cm, vertex
presentation, and intact membranes. Those ex-
cluded from participation were patients with pre-
vious cesarean delivery for cephalopelvic dispro-
portion, severe asthma, overt cervicitis, nonreassur-
ing fetal testing, fetal macrosomia, multiple
gestation, and those with any contraindication to
vaginal delivery. The University of Chicago group
B streptococcus screening policy at that time in-
cluded universal rectovaginal cultures for group B
streptococcus at 29 weeks of gestation, with anti-
biotic treatment for all those with positive cultures
in labor. Patients were randomized to treatment
using a computer-generated randomization chart,
and assignments were contained within sequential
opaque envelopes kept in the labor and delivery
suites. Informed written consent was obtained
from all enrolled patients. The study was approved
by the University of Chicago Institutional Review
Board.
Patients randomized to prostaglandin only re-
ceived an initial dose of 0.5 mg of Prepidil Gel (R)
(Upjohn, Kalamazoo, MI) using the following tech-
nique for administration. During a sterile speculum
examination, the Prepidil Gel (R) was instilled into
the cervix at the level of the internal os, according
to the packaging instructions. The patient then re-
mained in the labor and delivery area for continu-
ous fetal heart and tocodynamic monitoring. Reex-
amination of the cervix occurred after six hours, at
which time a second dose of 0.5 mg of Prepidil
Gel (R) was administered in the same fashion.
Patients randomized to the combined therapy
group also underwent sterile speculum examina-
tion, and the cervix and upper vagina were
cleansed with povidone-iodine. The anterior lip of
the cervix was stabilized with sterile ring forceps,
and a single dose of 0.5 mg of Prepidil Gel (R) was
placed intracervically as previously described. Us-
ing gentle traction on the cervix, a Dilapan(R) hygro-
scopic dilator (Gynotech, Middlesex, NJ), measur-
ing 4 x 55 mm, was inserted into the cervical canal
to the level of the internal os or until its hub was
flush with the external os. Additional dilators were
placed at that time until no more could be readily
inserted, usually between three and seven. The
upper vagina was then packed with sterile gauze to
assure the position of the dilators. After 6 hours of
continuous fetal and tocodynamic monitoring, the
Dilapan(R) were removed, the cervix reassessed, and
a second dose of 0.5 mg Prepidil (R) administered.
After the 12 hour preinduction study phase, rou-
tine obstetric care was instituted as usual. This
might include use of a third dose of Prepidil Gel (R)
if the Bishop score was less than 5, initiation of
oxytocin, and amniotomy. Decisions regarding the
use of labor analgesia and the option of cesarean
delivery were left to the discretion of the managing
team in the labor and delivery section. None of the
enrolled patients received antibiotic therapy before
enrollment in the study.
Chorioamnionitis was diagnosed by an intrapar-
turn temperature greater than 38.0C in the ab-
sence of any other identifiable cause for fever and
any of the following factors: fetal tachycardia, fun-
dal tenderness, or foul-smelling amniotic fluid. En-
domyometritis was defined as a temperature of
greater than 38.4C within the first 24 hours fol-
lowing delivery or greater than 38.0C after 24
hours postpartum, in addition to one of the follow-
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TABLE 2. Patient demographics
Dilapan (R) and Prepidil
(R)
(n 22)
Prepidil (R) only
(n 17) P-value
Age (years) 22.9 + 5.2 23.6 + 7.
Race:
African American 19 (86.4%) 16 (94. I%)
White 3 (I 3.6%) (5.9%)
Parity
0 13 (59. I%) 9 (52.9%)
-> 9 (40.9%) 8 (47. I%)
Mean .77 + 1.3 1.24 + 1.7
Gestation age (weeks)
All 38.8 + 2.2 39.3 + 2.3
34-36 4 (I 8.2%) 4 (23.5%)
->37 18 (81.8%) 13 (76.5%)
Bishop score at onset 2.3 + 1.2 2.8 + 1.5
Previous cesarean delivery 4 (18%) (5%)
Anesthesia
Epidural 19 (86.4%) 15 (88.2%)
Other 3 (I 3.6%) 2 (I 1.8%)
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
Data are presented as mean + standard deviation or n (%). NS, not significant.
ing: uterine tenderness, elevated white blood cell
count, or purulent vaginal discharge.
Primary outcome variables to be analyzed in-
cluded hours from induction to delivery, change in
modified Bishop score, and intrauterine infection.
Also compared were cesarean delivery rate, labor
onset during ripening, operative vaginal delivery,
percent of patients delivered before 24 hours, uter-
ine hypertonus, fetal heart rate abnormalities, Ap-
gar scores, and cord blood pH values.
Using the induction-to-delivery interval as the
outcome variable, a power calculation revealed that
136 patients were required for enrollment in order
to demonstrate a 2-hour difference in induction-to-
delivery interval with 80% power and an alpha of
0.05. Continuous variables were analyzed using the
Wilcoxon sum rank test and categorical data were
analyzed by Chi-square or the Fisher exact test,
with P < 0.05 considered to be statistically signifi-
cant.
RESULTS
A total of 44 patients were enrolled in the study.
Information was available for 43 patients. Four pa-
tients were randomized but excluded from the
study prior to the administration of the study medi-
cations. Of the four, one patient was discovered to
have severe asthma, one developed repetitive de-
celerations prior to induction, and two were noted
(upon review of the medical records chart) to have
undergone previous cesarean delivery for cephalo-
pelvic disproportion. Of the remainder, 22 patients
received combined therapy and 17 patients re-
ceived prostaglandin alone. Enrollment ended pre-
maturely in May 1995 when Gynotech removed
Dilapan(R) from the United States market.
There were no significant differences between
groups with respect to maternal age, race, parity,
gestational age, or Bishop score at the start of in-
duction (Table 2), as well as no difference in du-
ration of rupture of membranes and intraprtum
number of vaginal exams. Indications for induction
of labor are listed in Table 3, the most common
being hypertensive disorders and past-due dates,
an acceptable indication at our institution, where
many patients undergo induction of labor when
their gestations extend beyond 41 weeks.
Delivery outcomes are displayed in Table 4.
The overall cesarean delivery rate was 25.6%, while
the operative vaginal delivery rate was 20.5%.
There was a trend toward a higher cesarean deliv-
ery rate in the Dilapan (R) plus Prepidil (R) group
(36.4%) compared with the Prepidil (R) only group
(11.8%), though this did not reach statistical sig-
nificance (P 0.083). There were no significant
differences in birth weights, five-minute Apgar
scores less than 5, or cord pH values less than 7.20.
The combined Dilapan (R) and Prepidil (R) group
achieved a greater change in modified Bishop score
in the first 6 hours of induction when compared
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TABLE 3. Indication for labor induction
Dilapan
(R) and
Prepidil (R) Prepidil (R) only
(n 22) (n 17)
Past-dates (>41 weeks) 6 ,6
Diabetes 3
Hypertension and 10 6
preeclampsia
Growth retardation
Oligohydramnios
History of fetal demise 0
Fetal tachyarrhythmia 0
Rh isoimmunization 0
with the Prepidil (R) group (3.63 ___
1.8 vs. 2.05 +_ 1.3,
P 0.0074, Table 5. Of those patients who were
delivered vaginally, there was a shorter induction
to delivery interval noted in the combined group
(21.7 __+ 6.2 hours) compared with the Prepidil (R)
alone group (26.4 ___
9.6 hours); however, this trend
did not reach statistical significance (P 0.0847,
Table 5). A greater percentage of patients were
delivered by 24 hours in the combined group as
compared with the prostaglandin only group
(40.9% vs. 29.4%, P 0.097, Table 5). There was
no difference in the need for a third dose of Prepi-
dil (R) or the number of patients reaching active labor
in 12 hours. In our study group, patients with en-
dometritis and chorioamnionitis cultures showed
organisms of the aerobic gram-negative bacilli
group, mainly Escherichia coli, as well as anaerobic
gram-negative bacilli, as well as aerobic gram-
positive cocci, mainly Streptococcus agalactiae.
Table 6 shows the differences in maternal in-
fectious morbidity between the two groups. Cho-
rioamnionitis or endometritis occurred in 59% of
patients who received Dilapan (R) and Prepidil (R),
compared with 12% of patients in the single-agent
Prepidil (R) only group. When stratified by mode of
delivery, the difference remained statistically sig-
nificant for those who delivered vaginally (50% vs.
6.7%, P 0.0126). The rate of infection among
those in the combined treatment group who had
cesarean deliveries was not different from those
who received prostaglandin alone (75% vs. 50%),
but the number of patients in this category was
very small.
Five patients in the combined group had cesar-
ean deliveries for failure to progress, all at greater
than 4 cm of cervical dilation, compared with two
patients in the prostaglandin-only group. The .re-
maining three cesarean deliveries in the combined
group were performed for fetal distress occurring
remote from delivery, as well as remote from the
study treatments. There were no instances of post-
partum hemorrhage, uterine hypertonus, uterine
rupture, or neonatal death.
DISCUSSION
In this prospective, randomized, controlled trial,
we were able to demonstrate that combining hy-
groscopic dilators with intracervical prostaglandin
gel led to a greater change in cervical exam, as
compared with prostaglandin gel alone. This dif-
ference between the two groups of patients per-
sisted at 12 hours and may have led to the overall
shorter induction-to-delivery interval observed in
the combined therapy group, though these results
did not reach statistical significance. The percent-
age of patients reaching active labor in the first 12
hours of treatment and the number delivered by 24
hours was also greater in the combined treatment
group. The observed difference in cervical scores
was not at the expense of fetal well-being, as evi-
denced by similar Apgar scores, umbilical cord
blood gases, incidences of fetal distress, and heart
rate decelerations.
We were unable to locate any previous investi-
gations that evaluate the combination of mechani-
cal methods with prostaglandin gel for cervical rip-
ening. A recent randomized comparison by
Sanchez-Ramos et al.6 of the efficacy of hygro-
scopic cervical dilators versus prostaglandin gel
noted no significant difference in change in Bishop
score, amniotomy-to-delivery time, and maximum
dose of oxytocin. A comparison of a synthetic poly-
vinyl sponge dilator containing magnesium sulfate
(Lamicel(R)) to PGE 2 vaginal gel found the agents to
be equally effective. 14 Keirse, in a systematic re-
view of well-performed investigations regarding
cervical ripening, indicates that prostaglandin ad-
ministration is more likely to result in the onset of
labor than is the insertion of mechanical devices, as
We did not include a Dilapan (R) only arm in the
present investigation, so a direct comparison is not
possible with this previous work. However, it may
be that the significant difference we noted in cer-
vical score achieved with combination therapy is
related to a synergistic effect obtained by adding
prostaglandin gel to the cervical dilators.
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TABLE 4. Delivery outcomes
Dilapan (R) and Prepidil (R)
(n 22)
Prepidil (R) only
(n 17) P-value
Relative risk
[9S% confidence interval]
Vaginal delivery 14 (63.6%) 15 (88.2%)
Operative vaginal delivery 4 (18.2%) 4 (23.5%)
Cesarean delivery 8 (36.4%) 2 (11.8%)
Birth weight (g) 3149 + 542 3026 +/- 661
5-minute Apgar <5 0 0
Arterial umbilical cord pH <7.20 4 (18.2%) 3 (17.7%)
NS
NS
0.083
NS
NS
NS
3.09 [0.75-12.72]
Data are presented as mean + standard deviation or n (%). NS, not significant.
TABLE 5. Cervical ripening outcomes
Dilapan (R) and Prepidil
(R) Prepidil
(R) only
(n 22) (n 17) P-value
Change in Bishop score in first 6 hours
Induction-to-delivery interval (hours)
Delivered by 24 hours
Third dose of Prepidil
Active labor in 12 hours
3.6 +/- 1.8 2.1 +/- 1.3 0.0074
21.7 +/- 6.2 26.41 +/- 9.6 0.0847
9 (40.9%) 5 (29.4%) 0.097
7 (31.8%) 7 (41.2%) 0.496
14 (63.6%) 8 (47. I%) 0.239
Data are presented as mean + standard deviation or n (%).
TABLE 6. Maternal infection
Dilapan (R) and Prepidil (R)
(n 22)
Prepidil
(R) only Relative risk
(n 17) P-value [95% confidence interval]
All patients 13 (59%)
Vaginal 7/14 (50%)
Cesarean delivery 6/8 (75%)
2 (I 2%) 0.0029 5.02 [I .3 I-I 9.33]
1115 (6.7%) 0.0126 7.50 [1.05-53.49]
112 (50%) 0.533
The most concerning finding in our study is the
high rate of intrauterine infection in the combined
treatment group. Of those patients randomized to
combined therapy, 59% developed chorioamnion-
iris or endometritis, compared with only 12% in the
single-agent prostaglandin group. Previous investi-
gations of cervical ripening agents with regard to
intrauterine infection are not in agreement.
Sanchez-Ramos et al.6 noted the rate of chorioam-
nionitis and endometritis in an intracervical pros-
taglandin gel group to be identical to that in a Di-
lapan(R) group (15% vs. 16.6%). In a direct compari-
son of Dilapan (R) and laminaria, Blumenthal and
Ramanauskas1 found no intrapartum pyrexia or in-
fection in either group. Lin et al. 12 compared lami-
naria with extraamniotic saline infusions and re-
ported a 30.8% intrauterine infection rate in the
laminaria group. Kazzi et al. 11 noted a very high
rate of intrauterine infection, 60%, in a retrospec-
tive study in which laminaria tents were used for
cervical ripening, compared with only 11% in the
control group. Furthermore, five cases of neonatal
sepsis occurred in the laminaria group, while none
were noted in the control group. Interestingly, our
maternal infectious morbidity rate in the combined
dilator and prostaglandin group is almost identical
to that of Kazzi et al.’s 11 laminaria group.
In the current study the high infection rate was
unexpected. Theoretically, manipulation of the
cervix may increase the likelihood of bacterial as-
cension to the uterine cavity. Combining dilators
with intracervical gel increases cervical manipula-
tion, which may lead to higher infection rates.
Overt cervicitis was an exclusion factor for this
study. All patients were cultured at their first pre-
natal visit for Ndsseria gonorrhoeae and Chlamydia
trachomatis, and those with positive results were
treated at that time. Clinical screening for group B
streptococcus was performed at 28 weeks of gesta-
tion. Cervical cultures were not routinely obtained
at the time of admission for labor induction. The
high rate of intrauterine infection is important in
that it may have an impact on clinical problems
during labor, including a dysfunctional labor pat-
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tern and fetal stress. The presence of fever during
labor necessitates the initiation of intravenous an-
tibiotics for the gravida, usually continued after de-
livery and also for the neonate until sepsis has been
ruled out. This management scheme not only in-
creases the cost of care, but also lengthens the hos-
pital stay for mother and newborn.
Women who begin labor with a more advanced
cervical exam are known to have a shorter induc-
tion period and a greater chance for vaginal deliv-
ery compared with those with unripe cervices. ,13
For this reason, after noting better cervical ripening
in the combined therapy group, we anticipated that
this cohort might have had a lower cesarean deliv-
ery rate than the prostaglandin only group. How-
ever, we were surprised to note a trend toward a
higher cesarean delivery rate in the combined
therapy group. Again, the high incidence of mater-
nal infectious morbidity may have contributed to
the higher rate of operative deliveries. It is impor-
tant to note that the high maternal infection rate in
the combined therapy group persisted, even when
considering only those patients delivering vagi-
nally.
The current study ended abruptly in May 1995
when Dilapan (R) was removed from the United
States market by Gynotech, resulting in our much
smaller than anticipated sample size. While a sig-
nificant difference in cervical scores and infection
rates were noted, additional conclusions are lim-
ited. We realize that type II statistical errors may
readily occur in this small study. We considered
changing the protocol to continue the study with
generic laminaria; however, differences in the effi-
cacy of laminaria compared with Dilapan (R) may
have prevented a meaningful comparison. The
addition of a Dilapan (R) only arm would have im-
proved our study design, but an even larger sample
size would have been required. Bias in our study
may have occurred because the physician deter-
mining the posttreatment cervical score was aware
of the treatment arm to which each patient was
randomized. A double-blinded study would elimi-
nate this bias but would be difficult to conduct
with the personnel available and the structure of
the resident service in this large teaching hospital.
Decisions regarding other important outcomes
such as cesarean delivery and timing of delivery,
however, involved management by a larger group
of physicians, lessening the influence of individual
bias.
CONCLUSION
Combining hygroscopic cervical dilators with pros-
taglandin gel leads to more effective cervical rip-
ening and a potentially more rapid induction to
delivery interval than administering prostaglandin
alone. Unfortunately, these benefits are out-
weighed by a significant and prohibitively high rate
of intrauterine infection. While awaiting a larger,
more comprehensive evaluation of these methods,
the clinician faces the dilemma of whether achiev-
ing a more rapid delivery is worth the risk of the
maternal infectious morbidity noted in our pro-
spective trial.
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